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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 COVID-19: 
Real-time 
forecasts of 
confirmed 
cases, active 
cases, and 
health 
infrastructure 
requirements 
for India and its 
majorly 
affected States 
using the 
ARIMA model 
 
medRxiv| 
preprint (not 
peer 
reviewed) 
 
 This study forecasts the confirmed 
and active cases for C19 until June, 
using time series ARIMA model, and 
based on predicted active cases 
estimates required isolation beds, 
ICU beds and ventilators for C19 
patients 
 Forecasts are 441,896 confirmed 
cases (95% CI 210,240 to 673,552), 
124,712 active cases (95% CI 68,481 
to 180,944) by the end of June 
 Estimates require 106,006 isolation 
beds (95% CI 58,209 to 153,802), 
12,471 ICU beds (95% CI 6,848 to 
18,094) and 6,236 ventilators (95% 
CI 3,424 to 9,047) to accommodate 
this forecast 
 Authors suggest a Public-Private-
Partnership model in the health 
sector to accommodate C19 patients 
and reduce the burden on the Indian 
public healthcare system 
 
2 
Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
21.05.2020 Recombination 
potential of 
SARS-CoV-2 
and MERS-CoV 
iScience | 
SSRN 
 This study suggests that 
recombination between SARS-CoV-
2 and MERS-CoV RNA is possible  
 Public health laboratories in high-
risk areas should develop diagnostic 
capability for the detection of 
recombined coronaviruses in patient 
samples 
 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 Hydroxychloroquine 
or chloroquine with 
or without a 
macrolide for the 
treatment of COVID-
19: a multinational 
registry analysis 
The Lancet | 
Article 
 This observational study of 
96,032 patients with C19, 14,888 
of whom were treated with 
hydroxychloroquine, 
chloroquine, or their combination 
with a macrolide, across six 
continents evaluated real-world 
evidence related to outcomes 
with the use of 
hydroxychloroquine or 
chloroquine in the absence of 
reported randomised trials  
 Although observational studies 
cannot fully account for 
unmeasured confounding factors 
no evidence of benefit of 
hydroxychloroquine or 
chloroquine when either used 
alone or with a macrolide was 
found and also potential harm 
(decreased in-hospital survival 
and an increased frequency of 
ventricular arrhythmias) with the 
use of hydroxychloroquine or 
chloroquine drug regimens (with 
or without macrolide) in 
hospitalised patients with C19 
3 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 Safety, 
tolerability, and 
immunogenicity 
of a recombinant 
adenovirus type-
5 vectored 
COVID-19 
vaccine: a dose-
escalation, open-
label, non-
randomised, 
first-in-human 
trial 
The Lancet | 
Article 
 This first-in-human trial showed that 
the Ad5 vectored COVID-19 
vaccine is tolerable and 
immunogenic in healthy adults at 28 
days post-vaccination.  
 Humoral responses against SARS-
CoV-2 peaked at day 28 post-
vaccination in healthy adults, and 
rapid specific T-cell responses were 
noted from day 14 post-vaccination 
 This study suggests there is 
potential for further investigation of 
this vaccine candidate 
 An ongoing phase 2 trial in 
China will provide more 
information on the safety and 
immunogenicity of this vaccine 
candidate 
20.05.2020 DNA vaccine 
protection 
against SARS-
CoV-2 in rhesus 
macaques 
Science | 
Article 
 DNA vaccine candidates expressing 
different forms of the SARS-CoV-2 
Spike (S) protein elicited 
neutralising antibody titres which 
correlated with protection against 
SARS-CoV-2 in nonhuman primates 
Indirect impact of COVID-19 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
22.05.2020 Prevalence of 
mental health 
problems 
during virus 
epidemics int 
eh general 
public, health 
care workers 
and 
survivors: a 
rapid review 
medRxiv | 
Review (not 
peer 
reviewed) 
 A rapid review of mental health 
problems (MHP) prevalence rates 
published since 2000, during and after 
epidemics, including the general public, 
healthcare workers and survivors 
 Most original studies on MHP were 
conducted in China in the context of 
SARS-CoV-1, and reported anxiety, 
depression, post-traumatic stress 
symptoms/disorder, general psychiatric 
morbidity, and psychological symptoms 
 The MHP rates across studies, 
populations and epidemics vary 
substantially 
4 
of the 
evidence 
 Results call for the use of validated and 
standardised instruments, reference 
norms, and pre-post measurements to 
better understand the magnitude of the 
MHP during and after epidemics 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | 
Article type 
Author(s) 
22.05.2020 Chloroquine or hydroxychloroquine for 
COVID-19: why might they be hazardous? 
The Lancet | 
Comment 
Christian Funck-
Brentano 
Joe-Elie Salem 
22.05.2020 Children appear half as likely to catch 
COVID-19 as adults 
UCL | News  
21.05.2020 Covid-19 and the impact on gender and 
sexuality 
IDS | Opinion Susie Jolly 
21.05.2020 Survey suggests rising risk of food and 
nutrition insecurity in Addis Ababa, 
Ethiopia as COVID-19 restrictions 
continue 
IFPRI | Blog Kalle Hirvonen 
Gashaw Tadesse 
Abate 
Alan De Brauw 
21.05.2020 The economic impact of Covid-19 around 
the world: remittances, updated growth 
and poverty projections, and the 
reintroduction of Barter in Fiji 
CGD David Evans 
Amina Mendez 
Acosta 
20.05.2020 Coronavirus: everyone wins when patents 
are pooled 
Nature | 
Editorial 
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Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
21.05.2020 Revealing the toll of 
COVID-19 
Prevent 
Epidemics | 
Tool 
 This technical package helps guide 
governments in rapid mortality 
surveillance, informing decision-
making based on the true impact of 
C19 within their countries 
May 2020 Key considerations 
for COVID-19 
management in 
marginalised 
populations in 
Southeast Asia: 
transnational 
migrants, informal 
workers, and people 
living in informal 
settlements 
SSHAP | 
Briefings 
 This brief presents considerations of 
C19 management among 
structurally vulnerable populations in 
SE Asia including transnational 
migrants, people working in the 
informal economy, and people living 
in informal urban and peri-urban 
settlements 
 These populations are poorly 
understood ignored or left out of 
formal policy 
 Whilst not a systematic study of C19 
control measures, does include 
information on alternative parallel, or 
informal responses that are relevant 
to C19 control in the region 
May 2020 Key considerations: 
Covid-19 in the 
context of conflict 
and displacement – 
Myanmar 
SSHAP | 
Briefing 
 This brief focuses on how the 
interplay between conflict, 
displacement and inter-communal 
tensions in Myanmar may influence 
disease control 
 The response to C19 must be 
sensitive and effective where there 
are social and political challenges 
and where trust in authorities 
imposing diseases control may be 
low 
 A range of non-state actors must be 
factored into a public health 
response 
  
6 
Dashboards & Trackers 
Cases & 
deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living 
evidence 
& policy 
maps 
Current 
research 
including trials 
  Diagnosti
cs 
  Treatment
s 
  Vaccin
es 
WHO 
sitreps 
WHO 
Africa 
Ghana COVID-
NMA 
WHO   FIND 
SARS-
CoV-2 Test 
Tracker 
  Global 
COVID-19 
Clinical 
Trial 
Tracker 
  CEPI 
WHO 
dashboard 
African 
Argumen
ts 
Indonesi
a 
EPPI 
Centre 
WHO 
International 
Clinical Trials 
Registry 
Platform 
(ICTRP) 
 FIND 
SARS-
CoV-2 
Diagnostic
s: 
performanc
e data 
  US NIH 
registered 
clinical 
trials 
Vaccine 
Centre 
LSHTM 
Johns 
Hopkins 
University 
Europea
n CDC 
Nigeria 
CDC 
Norwegian 
Institute of 
Public 
Health 
Cytel  Serology-
based 
tests for 
COVID-19 
  Solidarity 
trial 
 COVID-
19 
Oxford 
Vaccine 
Trial 
WEF 
  Sierra 
Leone 
 Oxford 
C19 
Governme
nt 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World 
in Data: 
C19 
Testing 
  COVID-
19 
Therapeuti
cs 
Accelerator 
  
Our World 
in Data 
  Singapor
e 
 Our World 
in Data: 
C19 Policy 
responses 
COVID-
evidence 
      
Global 
5050 
  UK  IFPRI 
COVID-19 
Policy 
Cochrane       
7 
Response 
Portal 
CEBM, 
University 
of Oxford 
  US   Clinicaltrials.g
ov 
      
Humanitari
an Data 
Exchange 
       UKCDR       
Information 
is Beautiful 
              
LSHTM               
HealthMap 
(cases) 
              
The 
Commons 
Project 
              
 
C19 Resource Hubs 
Global  Region
al & 
Country 
Academi
c journals 
& 
Publisher
s 
Institutes/Centres/Funders/O
ther 
Health 
Topics 
  Social 
Sciences 
WHO COVID-
19 pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicatio
n 
African 
Union 
BMJ LSHTM 
 
  IDA 
8 
WHO Q&A Nigeria 
CDC 
Bulletin 
of the 
WHO 
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPol
l: 
SS
A 
Cambridg
e 
Universit
y Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University 
 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academ
y of 
Science
s 
Cochrane  Center for Global 
Development 
    Social 
Developme
nt Direct 
C19 blog 
series 
UN Women Africa 
Evidenc
e 
Network 
Elsevier CMMID Repository     
UNOCHA OCHA 
Souther
n and 
Eastern 
Africa 
COVID-
19 
Digest 
JAMA 
Network 
Norwegian Institute of Public 
Health 
    
UNHCR   The 
Lancet 
Oxford Centre for Evidence-
based Medicine 
    
UNICEF   medRxiv 
and 
bioRxiv 
(Preprints
) 
 HEART     
9 
UNESCO   NEJM  UKRI     
UN WFP   Oxford 
Universit
y Press 
 Evidence Aid     
GOARN   PLoS  NIH     
EPI-WIN   SAGE 
journals 
IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   Science  Prevent Epidemics      
Our World in 
Data 
  Springer 
Nature 
      
COVID-19 
Narratives by 
David 
Nabarro 
  SSRN 
(Preprints
)  
      
Reliefweb   Wiley       
Humanitarian 
OpenStreetM
ap Team 
          
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
10 
Premise 
COVID-19 
Global Impact 
Study 
    
  
Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
04.06.2020 
12pm ET 
CGD Conversations 
on COVID-19 and 
Development: John 
Nkengasong 
Event  CGD 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
11 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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